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INPATIENT RESOURCE UTILIZATION IN BRONCHIAL AND LUNG 
CANCER: ANALYSIS OF 2007 HEALTH CARE UTILIZATION AND 
PROJECT (HCUP) DATA
Patel B1, Kamal KM1, Atreja N2
1Duquesne University, Pittsburgh, PA, USA, 2Duquesne university, pittsburgh, PA, USA
OBJECTIVES: To assess overall inpatient resource utilization; and to identify patient-, 
and hospital-related predictors of inpatient length of stay (LOS), total charges, and 
inpatient mortality in bronchial and lung cancer. METHODS: A retrospective data-
base analysis was conducted using the 2007 Nationwide Inpatient Sample (NIS) 
database of the Health care Cost and Utilization Project (HCUP). Patient- (age, sex, 
payer) and hospital-related (private, teaching, region) characteristics were included in 
the study. Outcome variables were LOS, total charges, and inpatient mortality. 
Descriptive analysis examined the differences in bronchial and lung cancer-related 
outcome variables. Regression analyses were conducted to investigate the predictors 
of LOS, charges, and inpatient mortality in bronchial and lung cancer. All statistical 
analyses were conducted using SPSS 17.0 version. RESULTS: The hospital discharges 
for bronchial and lung cancer in 2007 NIS were 153,017 (52.38% male, 57.59% in 
age group 65–84). Mean LOS was 7.3 ± 0.1 days, mean charges were $45,473 ± 1,079, 
and inpatient mortality was 11.42%. Majority (89.0%) of the hospitalizations were 
located in metropolitan areas. Most hospitalizations (76.45%) were in private, not-
for-proﬁt hospitals. Medicare was the most common payer for the hospitalizations. 
Total charges were highest for hospitalizations identiﬁed in the Western region 
($65,655) and in private, for proﬁt hospitals ($59,233). Inpatient mortality was 
highest among hospitalizations in non-metropolitan areas (16.06%). CONCLU-
SIONS: Bronchial and lung cancer is the second leading cause of death in United States 
and thus, it is important to characterize resource utilization and important predictors 
for the disease. Patient- and hospital-related characteristics identiﬁed from this study 
will be useful in stratifying high-risk individuals and those with high inpatient resource 
utilization. Disease management programs such as smoking cessation programs can 
be implemented in high-risk population which can improve patient well-being, reduce 
hospitalizations, and promote cost savings.
CANCER – Patient-Reported Outcomes Studies
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EFFECTS OF VA ONCWATCH INTERVENTION ON COLORECTAL 
CANCER SCREENING ADHERENCE
Bian J1, Fisher D2, Lipscomb J3, Ribeiro M1, Byrd-Sellers J1
1Atlanta VAMC, Decatur, GA, USA, 2Duke University, Durham, NC, USA, 3Emory 
University, Rollins School of Public Health, Atlanta, GA, USA
OBJECTIVES: In 2008, the Veterans Integrated Service Network (VISN) 7 imple-
mented the colorectal cancer (CRC) Oncology Watch intervention (OncWatch), an IT 
system aimed at improving screening adherence and expanding use of colonoscopy 
for diagnostic and surveillance follow-ups. This study is to evaluate the effects of the 
OncWatch on CRC screening adherence. METHODS: We used 1998–2009 Veterans 
Affairs (VA) administrative data to construct two cohorts of average-risk, age 50–64 
veterans eligible for CRC screening, one for 2007 and the other for 2009. Average-
risk, age 50–64 veterans across the VA in 2007 or 2009 were included in this study. 
Veterans in a cohort for a year were considered adherent if they completed fecal occult 
blood test during that year, ﬂexible sigmoidoscopy or double-contrast barium enema 
during that year or the 4 previous years, or colonoscopy during that year or the 9 
previous years. Using a difference-in-differences approach, we applied multivariable 
linear probability models with hospitals ﬁxed-effects for estimation. RESULTS: The 
proportions of veterans adherent to screening in VISN 7 (including 9 hospitals) were 
31.62% in 2007 and 34.37% in 2009; and the proportions in the control VISNs 
(including 120 hospitals) 30.27% and 32.33%, respectively. Among the screening 
adherent, the proportions adherent to colonoscopy in VISN 7 were 16.44% in 2007 
and 24.40% in 2009; the proportions in the control VISNs 26.16% and 38.59%, 
respectively. The multivariable analyses showed that OncWatch was associated with 
a one-percentage-point increase in the likelihood of adherence among the veterans 
eligible for screening and a 3-percentage-point decrease in the likelihood of screening 
colonoscopy among the adherent (P < 0.001). CONCLUSIONS: This preliminary 
study suggests that OncWatch slightly increased the overall likelihood of screening 
adherence among average-risk, age 50–64 veterans. However, OncWatch may have 
unintentionally reduced use of screening colonoscopy, possibly because limited colo-
noscopy capacity was diverted from screening indications to diagnostic and surveil-
lance indications.
PCN103
A REVIEW AND META-ANALYSIS OF COLORECTAL CANCER UTILITIES
Djalalov S1, Hoch J2, Tomlinson G3
1CRICH, Toronto, ON, Canada, 2Cancer Care Ontario, Toronto, ON, Canada, 3Toronto 
General Research Institute, Toronto, ON, Canada
OBJECTIVES: To perform a systematic review of the literature on the utility weights 
for colorectal cancer (CRC) health states; to determine the effects of study character-
istics and role of “time to/from initial care” on utility values. METHODS: In a sys-
tematic review we identiﬁed 26 articles in English, providing 161 unique utilities for 
CRC health states elicited from 3574 respondents. Some utilities were estimated from 
SF-36 scores. Data were analyzed using Ordinary Least Squares and Linear Mixed- 
Effects with CRC cancer type, condition, stage, time to/from initial care, instrument, 
administration and study design as independent variables. RESULTS: In the base 
model, the estimated utility of the reference case (scenario of a CRC patient on stage 
I-III in continues care and more than 1 year post-operation, rated by using EQ5D/
HUI3) was 0.72. Cancer type, condition, stages, time to/from initial care, instruments 
and study design were associated with utility differences of 0.08 to 0.30 (P < 0.05). 
Utilities derived by using EQ5D/HUI3 instrument were 0.09 lower than SG/TTO, 0.08 
lower than EQ5Dvas and 0.09 lower than SF-36 (P < 0.01) in the base model of OLS 
analysis. Those utilities differences were signiﬁcantly larger in the supplemental model. 
Utilities elicited at “post-operation more than 1 year” were 0.15 higher than “preop-
erative”, 0.30 higher than “post-operation 1 year” in supplemental model. CONCLU-
SIONS: The CRC utilities review shows a lack of quality of life (QoL) studies for 
surveillance and terminal care that might cause high level uncertainty in the cost-
effectiveness analysis results. Pre- and post-operative health states and time to/from 
health intervention are important factors that inﬂuence QoL. Utilities appear sensitive 
to factors such as cancer type, time to/from initial care and utility instruments.
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ESTIMATION AND COMPARISON OF EQ-5D HEALTH STATES’ UTILITY 
WEIGHTS FOR PNEUMOCCOCAL AND HUMAN PAPILLOMAVIRUS 
DISEASES IN ARGENTINA, CHILE AND THE UNITED KINGDOM
Galante J1, Augustovski F1, Colantonio L1, Bardach A1, Garcia Marti S1, Caporale J1, 
Kind P2
1Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 2University of 
York, York, UK
OBJECTIVES: EQ-5D is a widely used generic health measure. One concern is the 
comparability of EQ5D derived weights of selected health states among different 
countries. Our objective was to estimate and compare EQ-5D health states’ weights 
for pneumoccocal and human papillomavirus (HPV) diseases in three different coun-
tries (Argentina, Chile and United Kingdom (UK). METHODS: Twelve health state 
vignettes (8 pneumococcal, 4 HPV) were designed and administered to a convenience 
sample in order to obtain descriptive data regarding the different disease-related 
EQ-5D health states. Subsequently, country speciﬁc EQ-5D time-trade off-based 
weights were used in order to map descriptive health states into local preference 
weights. Finally, inter-country differences for each condition were compared using 
repeated measures ANOVA. RESULTS: Between July and August 2009, 73 subjects 
(mean age = 31 years, range 22 to 58) successfully responded the questionnaire. Fifty-
three percent of the respondents were female and 96% worked or studied in the health 
sector. For pneumoccocal disease-related health states, utility coefﬁcients’ means 
ranged from −0.331 (sepsis, Chile) to 0.727 (auditive sequelae, Argentina). Regarding 
HPV-related conditions, their mean ranged from 0.152 (cervical cancer, UK) to 0.848 
(CIN1, Argentina). Chile consistently showed the lowest values in pneumococcal states 
and in one HPV state, while those of UK were the lowest in most HPV states. Argen-
tina showed the highest values in both disease groups. Mean differences between 
countries in pneumococcal health states were 0.256 (Argentina-Chile), 0.207(Argen-
tina-UK), and 0.048(Chile-UK); and those for HPV were 0.117 (Argentina-Chile), 
0.133 (Argentina-UK), and 0.017(Chile-UK). Differences in country-speciﬁc values for 
each health state were statistically signiﬁcant (p < 0.001). CONCLUSIONS: Preference 
weights for each condition differed signiﬁcantly between analyzed countries even 
though the same health states´ mix was valued for each. These results stress the 
importance of using local and not international weights in context-speciﬁc decision 
making processes.
PCN105
PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE 
FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) 
IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC 
BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR 
LETROZOLE ALONE
Delea TE1, Sofrygin O1, Amonkar M2
1PAI (Policy Analysis Inc.), Brookline, MA, USA, 2GlaxoSmithKline, Philadelphia, PA, USA
OBJECTIVES: The EGF30008 trial demonstrated that ﬁrst-line therapy with the 
combination of the anti-HER2 tyrosine kinase inhibitor lapatinib plus the aromatase 
inhibitor letrozole improves progression free survival vs. letrozole plus placebo among 
post-menopausal women with HER2+ and HR+ metastatic breast cancer (MBC). 
Results of analyses of the impact of lapatinib on patient health-related quality of life 
(QoL) based on FACT-B (Breast) questionnaire suggest that QoL was similar across 
treatment groups over 48 weeks. METHODS: This analyses estimated patient utility 
values for the treatment arms of EGF30008 using the FACT-G. Time-trade off (TTO) 
utility values were estimated using responses to 4 items from the FACT-G (Physical 
Well Being [PWB]-lack of energy, PWB-feel sick, Functional Well Being [FWB]-able 
to work, and FWB-able to enjoy life) and a published algorithm derived from 1433 
cancer patients (Dobrez 2007). For each patient in the EGF30008 trial, mean utility 
values were calculated for assessments before vs. on after progression. Pre- and post-
progression utilities were averaged across patients for each treatment group by weight-
ing patient level utilities by the numbers of assessments per patient. RESULTS: Among 
HER2+ patients, mean TTO utility values at baseline were 0.86 (0.10) for letrozole 
and lapatinib (N = 84) and 0.86 (0.09) for letrozole+placebo (N = 73). Mean (SD) 
pre-progression utilities were 0.86 (0.13) for letrozole+lapatinib (N = 102) and 0.88 
(0.13) for letrozole+placebo (N = 87). Utility values post-progression were based 
largely on a single assessment at disease progression for each patient and were 0.82 
(0.12) for letrozole+lapatinib (N = 63) and 0.82 (0.10) for letrozole+placebo (N = 57). 
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Results were similar in the ITT population (HER2+ or HER2- patients). CONCLU-
SIONS: Utility values for patients with HER2+ MBC are generally similar for patients 
receiving letrozole plus lapatinib or letrozole plus placebo. Post-progression utility 
values were based largely on a single assessment for each patient and are may not be 
representative of patient utility during all post-progression survival.
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IMPACT OF AN INDIVIDUAL’S LOCUS OF CONTROL ON UTILITY 
VALUES FOR HEAD AND NECK CANCER HEALTH STATES
Levy AR1, Szabo S1, Johnston K1, Dobson RL1, Donato BM2
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Bristol-Myers Squibb Co, Wallingford, CT, 
USA
OBJECTIVES: The determinants of utilities for health are largely unknown. The 
psychosocial construct Locus of control (LOC) describes the extent to which individu-
als feel their health is determined by their actions, by a powerful external ﬁgure, or 
by chance. LOC is associated with health-related quality of life among cancer patients 
but its impact on utilities has not been examined. The objective was to estimate the 
effect of LOC on utilities for head and neck cancer (HNC) health states among 
Canadians without cancer. METHODS: A convenience sample of respondents without 
cancer was recruited according to the age- and sex-distribution of Canada in Vancou-
ver and Toronto. Standard gamble utilities were elicited for health states describing 
HNC stage and type. Standardized health state descriptions were based on literature 
review, trial data, and feedback from clinicians experienced in HNC treatment and 
quality-of-life researchers. Respondents completed the validated Multidimensional 
Health LOC scale. Mixed regression models were used to determine associations 
between interval locus of control scores and utilities, adjusting for demographic 
variables, HNC stage and type. RESULTS: Utility values were elicited from 101 
respondents with a mean age of 47 years (48% male). Mean utilities were: 0.62 for 
locoregional laryngeal, 0.61 for locoregional non-laryngeal, 0.57 for recurrent non-
laryngeal, 0.56 for recurrent laryngeal, 0.52 for metastatic non-laryngeal, 0.50 for 
metastatic laryngeal, and 0.34 for post-progression, HNC. There was suggestive evi-
dence that LOC was associated with utilities (P = 0.079). Respondents who had a 
dominant Chance LOC rated health states signiﬁcant lower (P = 0.012): for every one 
unit increase on the Chance subscale, there was a decrement of 0.011 in mean utility 
value. CONCLUSIONS: This evidence indicates that LOC is a determinant of utilities 
for head and neck cancer health states. Replicating these ﬁndings in other populations 
and diseases would shed insight into the psychosocial determinants of preferences.
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EVALUATION OF QUALITY OF LIFE FOR ANTI-CANCER TREATMENT 
AMONGST KOREAN METASTATIC BREAST CANCER PATIENTS: A 
MULTICENTER, CROSS-SECTIONAL STUDY
Lee JY1, Ko SK1, Kim EJ2
1Pﬁzer Pharmaceuticals Korea Limited, Seoul, South Korea, 2Graduate School of Public 
Health, Seoul National University, Seoul, South Korea
OBJECTIVES: This research is designed to reveal Quality of life of Korean patients 
with metastatic breast cancer for cancer treatments. METHODS: This is a multicenter, 
cross-sectional study in breast cancer patients receiving palliative chemotherapy. Total 
199 patients with metastatic breast cancer were interviewed from 4 centers. Clinical, 
socio-demographic, and quality of life data were collected. Subjects completed a face-
to-face interview with trained interviewer to assess their health status for breast cancer 
treatment. Patients recalled the before diagnosis status under current situation. we 
used the three methods to evaluate the health status; EORTC QLQ-C30, BR-23, 
EQ-5D. RESULTS: Overall utility weights for EORTC QLQ C30 and EQ-5D was 
0.81 and 0.78 respectively(before diagnosis). It is higher than those of current 
(EORTC QLQ-C30: 0.54, EQ-5D: 0.60). the patients who are before diagnosis esti-
mated higher functioning score compared to current. (physical functioning scale; 
before cancer: 92.8, current 65.3) The higher the score is, the better patients’ function 
is. Symptom scale scores are the similar with functioning scale scores. The higher the 
score is, the worse the symptom is. before cancer status has lower symptom scale 
scores than current. (fatigue symptom scale; Before cancer: 25.2, current: 48.5) BR 
23 scale, there were deteriorations in patients for all domains compared to scores of 
before cancer patients. Especially, patient’ current body image score is signiﬁcantly 
lower than that of before diagnosis patients. (before diagnosis: 91.4, current: 46.4) 
CONCLUSIONS: There are few study of Quality of life in breast cancer patients. It 
is meaningful that this study provided the utility weights for breast cancer patients in 
Korea.
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PSYCHOMETRIC VALIDATION OF A PATIENT QUESTIONNAIRE 
EVALUATING SATISFACTION WITH A DARBEPOETIN ALPHA 
PRE-FILLED DEVICE FOR SELF-INJECTION 
(ARANESP®SURECLICKTMDEVICE), AND A HOME-SERVICE 
(2CARE®SERVICE) IN CHEMOTHERAPY-INDUCED ANAEMIC  
CANCER PATIENTS
de Jong FA1, Viala-Danten M2, van Herwaarden RH1, Poppe KA1, van Haaster CM1, 
Meunier J2, Rijnierse JJ1
1Amgen BV, Breda, The Netherlands, 2Mapi Values, Lyon, France
OBJECTIVES: To validate a questionnaire evaluating patient satisfaction with the 
darbepoetin alpha pre-ﬁlled device for self-injection (Aranesp®SureClickTMdevice) and 
the 2care®service for product delivery and helping patients with injection at home. 
METHODS: Patients with non-myeloid malignancies to be treated with 500mcg 
darbepoetin alfa three-weekly for chemotherapy-induced anaemia using the 
Aranesp®SureClickTMdevice and 2care®service were enrolled in a prospective, obser-
vational study in the The Netherlands. Following each of the ﬁrst three darbepoetin 
alpha-injections, patients completed a questionnaire speciﬁcally developed for this 
study. This questionnaire included items (answer ranges, 0–10) related to satisfaction 
with the device (5 items: ease-of-use/pain /anxiety/expectations/overall-satisfaction) 
and the 2care®service (9 items: quickness/delivery/punctuality/friendliness/compe-
tency/ﬂexibility/information/usefulness/overall-satisfaction). Questionnaire structure 
was deﬁned using factor analyses and conﬁrmed by multi-trait analysis. Internal 
consistency was evaluated by Cronbach’s alfa. Ranges of minimal important differ-
ences (MIDs) were calculated using anchor-based and distribution-based methods. 
Determinants of overall satisfaction with the Aranesp®SureClickTMdevice were ana-
lyzed by multiple regression analyses. RESULTS: A total of 283 patients were evalu-
able. At ﬁrst injection, median item-scores ranged from 8.0–9.4. Two composite scores 
were deﬁned (1 item not correlated with any scores: quickness 2care®-contact making 
appointment): satisfaction with the Aranesp®SureClickTMdevice and satisfaction with 
the 2care®service. Item-score correlations ranged from 0.61–0.81 and 0.64–0.79, 
respectively. Cronbach’s alfas were 0.85 and 0.84. All items met convergent and 
discriminant validity criteria. Plausible MIDs were 0.5–0.7 and 0.3 for satisfaction 
with the Aranesp®SureClickTMdevice and 2care®service, respectively. At ﬁrst injec-
tion, satisfaction with the Aranesp®SureClickTMdevice was mainly determined by 
expectations, pain, and ease-of-use. After 3 injections, the main driver was ease-of-use. 
CONCLUSIONS: Patients were satisﬁed with the Aranesp®SureClickTMdevice and 
2care®service. The satisfaction questionnaire showed good dimension structure and 
internal consistency reliability. MIDs were provided for interpretation of scores. 
Determinants of patient satisfaction were shown to change (ease-of-use becoming the 
main driver, while pain importance decreased) while the patient accumulates experi-
ence with the Aranesp®SureClickTMdevice.
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DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
(PRO-CTCAE)
Basch E1, Reeve B2, Cleeland C3, Sloan J4, Mendoza T3, Abernethy A5, Bruner D6, Hay J1, 
Atkinson T1, Sit L1, Minasian L2, O’Mara A2, Burke L7, Schrag D8
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2National Cancer Institute, 
Bethesda, MD, USA, 3U.T.M.D. Anderson Cancer Center, Houston, TX, USA, 4Mayo Clinic, 
Rochester, MN, USA, 5Duke University, Durham, NC, USA, 6University of Pennsylvania, 
Philadelphia, PA, USA, 7Food and Drug Administration, Silver Spring, MD, USA, 
8Dana-Farber Cancer Institute, Boston, MA, USA
OBJECTIVES: The standard lexicon for reporting adverse events in NCI-sponsored 
trials is the Common Terminology Criteria for Adverse Events (CTCAE), which 
consists of over 800 individual items. Currently, all items are reported by clinicians. 
However, multiple studies have found that clinicians tend to underreport symptom 
severity and onset compared with patient self-reports. In October 2008, the NCI 
contracted a multi-institution consortium to develop patient versions of CTCAE items, 
and an administration electronic platform. METHODS: A multidisciplinary commit-
tee systematically identiﬁed CTCAE items with sufﬁcient subjective component to be 
amenable to patient reporting. Systematic reviews of publications and existing ques-
tionnaires, and analyses of existing data sets were conducted to determine optimal 
formats for questions and response options, and plain-language terms for each new 
“PRO-CTCAE” item. Cognitive interviews were conducted in 100 patients to reﬁne 
items. RESULTS: Seventy-seven “symptoms” were identiﬁed in the CTCAE which 
were amenable to patient reporting. The committee determined that measured attri-
butes for each symptom should include frequency, severity, and activity interference, 
assessed via discrete questions for each symptom. A standardized format for questions 
and response options, and plain language terms for each symptom were formulated. 
A web-based platform was developed for creating and administering the new PRO-
CTCAE items. CONCLUSIONS: A patient version of the CTCAE system, known as 
the PRO-CTCAE, has been developed. This prototype is undergoing further testing 
to assess its validity, reliability, usability, and feasibility for use in a variety of cancer 
care settings. The PRO-CTCAE system both will enhance adverse event reporting by 
directly integrating patient experiences and will foster consistency of data collection 
methods across studies.
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HOW MUCH DO PATIENTS WITH RENAL CELL CARCINOMA (RCC) 
VALUE PROGRESSION FREE SURVIVAL IN MEDICAL DECISION 
MAKING?—RESULTS FROM A BENEFIT-RISK CONJOINT STUDY
Hauber AB1, Mohamed AF1, Johnson FR1, Neary MP2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals, 
Collegeville, PA, USA
BACKGROUND: Overall survival (OS) has been traditionally used as the primary 
endpoint in oncology trials, however cross-over to 2nd line agents may result in biases 
for OS. Recent trials have used progression free survival (PFS) as the primary endpoint. 
Understanding patient preferences regarding expected PFS vs. avoidance of risk for 
toxicities in medical decision-making is needed. OBJECTIVES: To estimate RCC 
patients’ willingness to accept toxicities and medication-related risks to increase PFS. 
METHODS: US residents aged 18 years and over with RCC completed a web-enabled, 
choice-format conjoint survey that presented a series of 12 trade-off questions, each 
including a pair of hypothetical RCC medication proﬁles. Each proﬁle was deﬁned by 
efﬁcacy (PFS), tolerability effects (fatigue, diarrhea, hand-foot syndrome, mouth 
